Johnson & Johnson (JNJ): New Buy Recommendation for This Healthcare Giant

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Johnson & Johnson (NYSE: JNJ). The company’s shares closed yesterday at $136.56.

According to, Selvaraju is ranked 0 out of 5 stars with an average return of -5.7% and a 33.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Johnson & Johnson is a Strong Buy with an average price target of $154, implying a 12.8% upside from current levels. In a report issued on October 12, Credit Suisse also maintained a Buy rating on the stock with a $149 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $148.32 and a one-year low of $118.62. Currently, Johnson & Johnson has an average volume of 6.15M.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.